Repligen
RGEN
404 hedge funds and large institutions have $8.16B invested in Repligen in 2022 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 151 increasing their positions, 149 reducing their positions, and 71 closing their positions.
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
2.64% more ownership
Funds ownership: 88.13% → 90.77% (+2.6%)
1% more repeat investments, than reductions
Existing positions increased: 151 | Existing positions reduced: 149
9% less capital invested
Capital invested by funds: $8.94B → $8.16B (-$778M)
10% less funds holding
Funds holding: 450 → 404 (-46)
16% less call options, than puts
Call options by funds: $34.6M | Put options by funds: $41.1M
55% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 71
Top Buyers
Top Sellers
RGEN Hedge Fund Activity: Q2 2022 in Review
404 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Repligen (RGEN) for Q2 2022, worth a combined $8.16B — down 8.7% from $8.94B a quarter earlier.
Sellers outnumbered buyers: 71 funds closed out of RGEN and 32 opened new positions — a net loss of 39 holders — while 149 trimmed existing stakes and 151 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $278M. The largest seller was Select Equity Group, cutting an estimated $148M.
- 404 institutional investors held Repligen (RGEN) as of Q2 2022, down from 450 in Q1 2022.
- Funds reported $8.16B of Repligen stock for Q2 2022, down 8.7% quarter-over-quarter.
- 32 funds opened new Repligen positions in Q2 2022 and 71 closed out, a net change of -39 holders.
- The largest Repligen buyer in Q2 2022 was T. Rowe Price Associates, an estimated $278M added.
- The largest Repligen seller in Q2 2022 was Select Equity Group, an estimated $148M sold.
Based on aggregated 13F filings for Q2 2022.